Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Jonathan Pachter"'
Autor:
Tobias Max Philipp Hartwich, Miranda Mansolf, Cem Demirkiran, Michelle Greenman, Stefania Bellone, Blair McNamara, Shuvro P. Nandi, Ludmil B. Alexandrov, Yang Yang‐Hartwich, Silvia Coma, Jonathan Pachter, Alessandro D. Santin
Publikováno v:
Cancer Medicine, Vol 13, Iss 17, Pp n/a-n/a (2024)
Abstract Background High‐grade endometrial cancers (EAC) are aggressive tumors with a high risk of progression after treatment. As EAC may harbor mutations in the RAS/MAPK pathways, we evaluated the preclinical in vitro and in vivo efficacy of avut
Externí odkaz:
https://doaj.org/article/c903116f7e7848cf816112aa15bc9253
Autor:
Simon Timbrell, Hosam Aglan, Angela Cramer, Phil Foden, David Weaver, Jonathan Pachter, Aoife Kilgallon, Robert B. Clarke, Gillian Farnie, Nigel J. Bundred
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-13 (2021)
Abstract Cancer stem-like cells (CSC) contribute to therapy resistance and recurrence. Focal adhesion kinase (FAK) has a role in CSC regulation. We determined the effect of FAK inhibition on breast CSC activity alone and in combination with adjuvant
Externí odkaz:
https://doaj.org/article/0042b7fcefc749e8a9c051f9adcd6bb2
Autor:
Qun-Sheng Ji, Neil W. Gibson, John D. Haley, Kenneth K. Iwata, David Epstein, Mark Miglarese, Jonathan Pachter, Yan Yao, Mathew O'Connor, Eric Brown, Sharon Barr, Mark Mulvihill, Stuart Thomson, Maryland Rosenfeld-Franklin, Alexandra Eyzaguirre, Elizabeth Buck
Supplementary Figures 1-6 from Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e7ec92813ce2f78c103c78d45e441de
https://doi.org/10.1158/0008-5472.22373438.v1
https://doi.org/10.1158/0008-5472.22373438.v1
Autor:
Qun-Sheng Ji, Neil W. Gibson, John D. Haley, Kenneth K. Iwata, David Epstein, Mark Miglarese, Jonathan Pachter, Yan Yao, Mathew O'Connor, Eric Brown, Sharon Barr, Mark Mulvihill, Stuart Thomson, Maryland Rosenfeld-Franklin, Alexandra Eyzaguirre, Elizabeth Buck
Supplementary Table 1 from Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b3ecdb7f42194c8fd4475413f56effa
https://doi.org/10.1158/0008-5472.22373432.v1
https://doi.org/10.1158/0008-5472.22373432.v1
Autor:
Qun-Sheng Ji, Neil W. Gibson, John D. Haley, Kenneth K. Iwata, David Epstein, Mark Miglarese, Jonathan Pachter, Yan Yao, Mathew O'Connor, Eric Brown, Sharon Barr, Mark Mulvihill, Stuart Thomson, Maryland Rosenfeld-Franklin, Alexandra Eyzaguirre, Elizabeth Buck
Supplementary Methods from Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f9b5436c6114fe395eb6c96eaf2aced
https://doi.org/10.1158/0008-5472.22373435.v1
https://doi.org/10.1158/0008-5472.22373435.v1
Autor:
Qun-Sheng Ji, Neil W. Gibson, John D. Haley, Kenneth K. Iwata, David Epstein, Mark Miglarese, Jonathan Pachter, Yan Yao, Mathew O'Connor, Eric Brown, Sharon Barr, Mark Mulvihill, Stuart Thomson, Maryland Rosenfeld-Franklin, Alexandra Eyzaguirre, Elizabeth Buck
Supplementary Figure Legends from Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5f6fa5f41b4f962721e810c3623ae1c
https://doi.org/10.1158/0008-5472.22373441
https://doi.org/10.1158/0008-5472.22373441
Autor:
Simon Rodney, Adam R. Stewart, Victoria Sanchez Perez, Cienne Morton, Lisa A. Pickard, Taleen Shakouri, Toby Prout, Mona Parmar, Alison J. Turner, Silvia Coma, Jonathan Pachter, Laura Finneran, Emma Hall, James Spicer, Anna Minchom, Udai Banerji
Publikováno v:
Cancer Research. 83:3461-3461
Background: KRAS mutations (mt) are found in ~30% of non-small cell lung cancers (NSCLC). Despite the approval and development of KRAS G12C and KRAS G12D inhibitors respectively, mechanisms of resistance to MAPK pathway inhibitors are emerging and co
Autor:
Parmeshwar Amatya, Alun Carter, Julie Ritchey, Reyka Jayasinghe, Matthew Cooper, Jonathan Pachter, John Dipersio
Publikováno v:
Cancer Genetics. :3-4
Autor:
Shih-Shih Chen, Jacqueline Barrientos, Gerardo Ferrer, Priyadarshini Ravichandran, Michael Ibrahim, Yasmine Kieso, Jeff Kutok, Marisa Peluso, Sujata Sharma, David Weaver, Jonathan Pachter, Kanti Rai, Nicholas Chiorazzi
Inhibitors of Bruton’s Tyrosine Kinase (BTKi) and phosphoinositide 3-kinase (PI3Ki) have significantly improved therapy of chronic lymphocytic leukemia (CLL). However, the emergence of resistance to BTKi has introduced an unmet therapeutic need. He
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1385a20f07af2ea0025892daa852548
https://doi.org/10.21203/rs.3.rs-701669/v1
https://doi.org/10.21203/rs.3.rs-701669/v1
Publikováno v:
Molecular Cancer Therapeutics. 20:P048-P048
Background: VS-6766 is a unique small molecule inhibitor of both RAF and MEK. In contrast to several other MEK inhibitors available, VS-6766 blocks both MEK kinase activity and RAF phosphorylation of MEK. This sequential blockade mechanism enables VS